STOCK TITAN
  1. Home
  2. News
  3. CMRX

Chimerix Inc - CMRX STOCK NEWS

Welcome to our dedicated news page for Chimerix (Ticker: CMRX), a resource for investors and traders seeking the latest updates and insights on Chimerix.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Chimerix's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Chimerix's position in the market.

News
Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024
Rhea-AI Summary
Chimerix (CMRX) will host a conference call on May 1, 2024, to report Q1 2024 financial results and provide a business overview. The call will discuss the company's progress in developing medicines for deadly diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.09%
Tags
conferences earnings
-
News
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Chimerix (CMRX) granted inducement awards to new employees in the form of stock options under Nasdaq Listing Rule 5635(c)(4). The awards total 223,000 shares of common stock with a 10-year term and vesting over four years. The options were granted at the closing trading price on the grant date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
none
-
News
Chimerix Appoints Marc D. Kozin to Board of Directors
Rhea-AI Summary
Chimerix (NASDAQ:CMRX) appoints Marc D. Kozin to its Board of Directors, with veteran industry executive bringing over 35 years of corporate strategy experience. Patrick Machado to retire after ten years of service. The company aims to advance its pipeline to commercialization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.43%
Tags
management
News
Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update
Rhea-AI Summary
Chimerix (CMRX) reports $204 million in cash and equivalents at December 31, 2023. ONC201 ACTION study progressing with interim OS data expected in 2025 and final OS data in 2026. Phase 2 ONC201 data published in a peer-reviewed journal. Company focuses on advancing clinical development and potential commercialization of ONC201.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.26%
Tags
earnings
-
News
Chimerix to Present at TD Cowen 44th Annual Health Care Conference
Rhea-AI Summary
Chimerix (CMRX) CEO to participate in Targeted Oncology Panel at TD Cowen 44th Annual Health Care Conference. Audio webcast available on Chimerix's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
conferences
-
News
Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024
Rhea-AI Summary
Chimerix (CMRX) to host conference call to report financial results for Q4 and full-year 2023, along with a business overview.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
conferences earnings
News
Chimerix Appoints Lisa Decker to Board of Directors
Rhea-AI Summary
Chimerix (NASDAQ:CMRX) appoints Lisa Decker, Chief Business Officer at IGM Biosciences, to its Board of Directors, replacing Catherine Gilliss PhD, RN, FAAN. Decker brings over 25 years of leadership and business development experience, including roles at Atreca Inc. and Nektar Therapeutics. Chimerix CEO, Mike Andriole, welcomes Decker's expertise, thanking Gilliss for her service.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.35%
Tags
management
-
News
Chimerix Promotes Michelle LaSpaluto to Chief Financial Officer
Rhea-AI Summary
Chimerix (NASDAQ:CMRX) announced the promotion of Michelle LaSpaluto to Chief Financial Officer, effective December 1, 2023. LaSpaluto, with more than 25 years of financial experience, will lead the company into its next growth phase. She has been a proven leader within the company and has played a pivotal role in various areas core to the CFO role, including capital raising, accounting, investor relations, internal controls, and business development transactions. Her deep familiarity with the company's operating structure and programs will enable a smooth transition to the expanded responsibility. LaSpaluto's promotion reflects the company's commitment to advancing its imipridone pipeline and building Chimerix into a leading oncology company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.97%
Tags
none
-
News
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Chimerix (CMRX) granted 150,000 non-qualified stock options to a new employee, with an exercise price of $1.00 per share. The stock option has a 10-year term, vesting over four years. Chimerix is a biopharmaceutical company focused on developing medicines, with its most advanced program, ONC201, in development for H3 K27M-mutant glioma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
none
News
Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer
Rhea-AI Summary
Chimerix (NASDAQ:CMRX) appoints Thomas Riga as Chief Operating and Commercial Officer, leveraging his 25 years of oncology commercialization and business development experience to advance ONC201 toward commercialization. Riga's previous leadership roles at Spectrum Pharmaceuticals, Dendreon, Amgen, and Eli Lilly and Company, coupled with his B.S. in Biology and Chemistry, position him to drive Chimerix's growth and bring potentially life-altering drugs to patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
management
Stock CMRX logo
Chimerix Inc

Nasdaq:CMRX

CMRX Rankings

#4441 Ranked by Market Cap
#4499 Ranked by Stock Gains
N/A Ranked by Dividends

CMRX Stock Data

85.70M
74.39M
1.34%
50.01%
1.39%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Durham

About CMRX

led by an experienced antiviral drug development team, chimerix is developing novel oral antiviral therapeutics with the potential to improve quality of life for patients in multiple settings, including transplant, oncology, acute care and global health. the company’s proprietary lipid technology has given rise to two clinical stage compounds, cmx001 and cmx157, which have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. chimerix’s lead compound, cmx001, is a broad spectrum lipid acyclic nucleoside phosphonate that inhibits double-stranded dna (dsdna) viruses including cytomegalovirus (cmv), adenovirus, bk virus, herpes simplex virus and variola (smallpox). cmx001 has completed phase 2 clinical development for the prophylaxis of cmv and is in phase 2 development for the preemption and treatment of adenovirus infection in hematopoietic stem cell transplant (hsct) recipients. to date, more than 750 patients have been dosed